Aclarion broadens CLARITY trial enrollment criteria to speed recruitment, readout timing under review
Bitget2026/10/08 11:02Aclarion broadened enrollment criteria for its pivotal CLARITY trial to speed recruiting and keep the study on its original timeline. Initial results have not been presented; timing for the first readout will be updated by year-end, reflecting stronger Q4 enrollment. Revised criteria are in place at nine of 11 active sites, with the remaining sites screening under the new framework. The change is intended to better match real-world chronic low back pain patients while preserving trial rigor. Management expects faster, more consistent enrollment, supporting a study population seen as more representative for eventual commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080700PRIMZONEFULLFEED9842010) on October 08, 2026, and is solely responsible for the information contained therein.
- Aclarion broadened enrollment criteria for its pivotal CLARITY trial to speed recruiting and keep the study on its original timeline.
- Initial results have not been presented; timing for the first readout will be updated by year-end, reflecting stronger Q4 enrollment.
- Revised criteria are in place at nine of 11 active sites, with the remaining sites screening under the new framework.
- The change is intended to better match real-world chronic low back pain patients while preserving trial rigor.
- Management expects faster, more consistent enrollment, supporting a study population seen as more representative for eventual commercialization.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
